Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Rated “Moderate Buy” by Sell-Side Analysts

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) has been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $8.33.

A number of research analysts have recently weighed in on WHWK shares. Stifel Nicolaus started coverage on Whitehawk Therapeutics in a research report on Wednesday, September 30th. They set a “buy” rating and a $9.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Wednesday, September 2nd. Wall Street Zen upgraded Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Leerink Partners assumed coverage on shares of Whitehawk Therapeutics in a research note on Monday, July 13th. They issued an “outperform” rating and a $9.00 price objective on the stock.

Institutional Trading of Whitehawk Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Montanova Capital LLC boosted its stake in Whitehawk Therapeutics by 16.2% in the second quarter. Montanova Capital LLC now owns 4,300,000 shares of the company’s stock valued at $19,694,000 after acquiring an additional 600,000 shares in the last quarter. Two Sigma Securities LLC purchased a new stake in Whitehawk Therapeutics in the 2nd quarter valued at $46,000. Bank of America Corp DE purchased a new stake in Whitehawk Therapeutics during the second quarter worth about $159,000. ADAR1 Capital Management LLC purchased a new position in shares of Whitehawk Therapeutics during the second quarter valued at approximately $6,144,000. Finally, BlackRock Inc. acquired a new position in shares of Whitehawk Therapeutics during the second quarter worth about $8,807,000. 52.08% of the stock is owned by hedge funds and other institutional investors.

Whitehawk Therapeutics Stock Performance

NASDAQ WHWK opened at $3.13 on Monday. Whitehawk Therapeutics has a 52-week low of $1.97 and a 52-week high of $5.49. The company’s fifty day moving average is $3.68 and its two-hundred day moving average is $3.83.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.10. Research analysts predict that Whitehawk Therapeutics will post -1.00 EPS for the current year.

Whitehawk Therapeutics Company Profile

Whitehawk Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for the treatment of serious diseases. The company’s activities center on advancing an internal pipeline of therapeutic candidates through preclinical research and clinical development.

Whitehawk Therapeutics does not appear to have marketed products at this stage. Its work is focused primarily on research and development, including evaluating potential drug candidates for safety, efficacy and suitability for further clinical testing.

Publicly available information about the company’s specific pipeline, operating geographies and leadership is limited.